New Combo Therapy for Untreated CLL Tops SPT Week in Review


Top news of the week from Specialty Pharmacy Times.

5. FDA OKs Relaunch of Novel Intravenous Immune Globulin Product

The FDA approved a Prior Approval Supplement for immune globulin intravenous (human), 10% liquid (Bivigam, ADMA Biologics) for patients with primary humoral immunodeficiency disease. Read more.

4. FDA Grants Breakthrough Designation to Treatment for Kaposi Sarcoma

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status. Read more.

3. FDA OKs First Anti-PD-L1 Therapy in Combo Regimen for Advanced Kidney Cancer

Avelumab (Bavencio) plus axitinib (Inlyta) is indicated for the first-line treatment of patients with advanced renal cell carcinoma. Read more.

2. FDA Committee Votes Against Quizartinib Approval for Acute Myeloid Leukemia

The FDA’s Oncology Drugs Advisory Committee challenged the results of the phase 3 QuANTUM-R study. Read more.

1. FDA Approves Combo Therapy for Untreated Chronic Lymphocytic Leukemia

The approval of venetoclax (Venclexta) in combination with obinutuzumab (Gazyva) offers an additional option for adults with previously-untreated chronic lymphocytic leukemia. Read more.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская |
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages -
Image credit: alicja neumiler |
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Pharmacist preparing high-risk chemotherapy
Image Credit: © jarun011 -
© 2024 MJH Life Sciences

All rights reserved.